180 Life Sciences Book/Share
What is the Book/Share of 180 Life Sciences?
The Book/Share of 180 Life Sciences Corp. is -0.02
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on NASDAQ compared to 180 Life Sciences
What does 180 Life Sciences do?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Companies with book/share similar to 180 Life Sciences
- Proteo has Book/Share of -0.02
- HFX has Book/Share of -0.02
- Aequus Pharmaceuticals has Book/Share of -0.02
- Shekel Brainweigh has Book/Share of -0.02
- Pascal Biosciences has Book/Share of -0.02
- Globally Local Technologies has Book/Share of -0.02
- 180 Life Sciences has Book/Share of -0.02
- Duesenberg Technologies has Book/Share of -0.02
- Memex has Book/Share of -0.02
- Branded Legacy Inc has Book/Share of -0.02
- Synstream has Book/Share of -0.02
- BioPharmX has Book/Share of -0.02
- Achiko AG has Book/Share of -0.02